AIM：To investigate the altering expression profiles of efflux transporters such as breast cancer-resistance protein（BCRP）,lung resistance protein（LRP）,and multidrug resistance protein 1（MDR1） at the inner blood...AIM：To investigate the altering expression profiles of efflux transporters such as breast cancer-resistance protein（BCRP）,lung resistance protein（LRP）,and multidrug resistance protein 1（MDR1） at the inner blood-retinal barrier（BRB） during the development of early diabetic retinopathy（DR） and/or aging in mice.METHODS：Relative m RNA and protein expression profiles of these three efflux transporters in the retina during the development of early DR and/or aging in mice were examined.The differing expression profiles of Zonula occludens 1（ ZO-1） and vascular endothelial growth factor-A（ VEGFA） in the retina as well as the perfusion characterization of fluorescein isothiocyanate（FITC）-dextran and Evans blue were examined to evaluate the integrity of the inner BRB.RESULTS：There were significant alterations in these three efflux transporters＇ expression profiles in the m RNA and protein levels of the retina during the development of diabetes mellitus and/or aging.The development of early DR was confirmed by the expression profiles of ZO-1 and VEGFA in the retina as well as the compromised integrity of the inner BRB.CONCLUSION：The expression profiles of some efflux transporters such as BCRP,LRP,and MDR1 in mice retina during diabetic and/or aging conditions are tested,and the attenuated expression of BCRP,LRP,and MDR1 along with the breakdown of the inner BRB is found,which may be linked to the pathogenesis of early DR.展开更多
Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-sma...Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-small cell lung cancer (NSCLC) was detected using immunohistochemistry method. The expression of MRP in 30 cases of NSCLC and corresponding normal lung tissues were detected using immunohistochemistry and Western Blot. Results: this study of tumor tissues confirmed the plasma membrane and/or cytoplasm locations of MRP. There was apparent difference between normal lung tissues and NSCLC in MRP. The survival analysis of 62 NSCLC showed that the mean survival time of the patients with negative MRP expression was 69.8117.41 months and that of patients with positive MRP expression, 25.384.46 months. Log-rank test suggested that the difference between them was significant (P=0.0156). It was also found that in squamous cell lung cancer the statistically significant difference between the mean survival time of patients with positive MRP expression and those with negative MRP expression (P=0.0153). Multivariate Cox model analysis suggested that the survival time was significantly related to expression of MRP (P=0.035) and lymphatic metastasis (P=0.038). Conclusion: MRP expression in NSCLC is significantly higher compared with normal lung tissues. The mean survival time of patients with negative MRP was relative longer and expression of MRP was an independent factor for prognosis.展开更多
目的研究乳腺癌组织中肺耐药蛋白(lung resistance protein,LRP)的表达,探讨其在乳腺癌多药耐药机制中的作用及其临床意义。方法2000年首都医科大学附属北京友谊医院普通外科收治的乳腺癌病例81例,均为女性,年龄30至83岁(平均年龄53.2...目的研究乳腺癌组织中肺耐药蛋白(lung resistance protein,LRP)的表达,探讨其在乳腺癌多药耐药机制中的作用及其临床意义。方法2000年首都医科大学附属北京友谊医院普通外科收治的乳腺癌病例81例,均为女性,年龄30至83岁(平均年龄53.2岁),接受以手术为主的综合治疗且均未进行新辅助化疗。病理类型包括浸润性导管癌、浸润性小叶癌、单纯癌、黏液癌和早期浸润癌。根据2003版国际抗癌联盟(International Union Against Cancer,UICC)乳腺癌分期标准进行临床病理分期,Ⅰ期:17例,Ⅱ期:43例,Ⅲ期:21例。术后5年随访者36例,无瘤生存30例,转移6例(带瘤生存1例,死亡5例)。制作组织芯片,采用SP免疫组化染色法,测定81例未经过新辅助化疗的乳腺癌标本中LRP的表达,与临床病理因素及雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、抑癌基因p53(p53)、人表皮生长因子受体2(Her-2)、增生细胞核抗原Ki-67(Ki-67)的表达进行相关性分析。应用χ2检验及等级相关检验,使用SPSS11.5统计学软件进行数据处理及分析。结果乳腺癌组织中LRP的阳性表达率为70.4%(57/81)。老年患者的LRP表达比中青年患者明显降低(P<0.05);LRP的表达与病理分期、预后无相关关系(P>0.05)。LRP与ER和PR的表达存在一定的正相关关系,相关系数分别为0.327、0.264(P<0.05);LRP与p53、Her-2、和Ki-67的表达无相关关系(P>0.05)。结论LRP在乳腺癌组织中有较高的表达率,与年龄及ER、PR的表达有关,本结果为临床化疗药物的选择提供了依据。展开更多
目的:探讨参慈胶囊对人肺腺癌A549/DDP裸鼠体内多药耐药相关基因的影响。方法:将50只C57BL/6小鼠接种人肺腺癌细胞A549/DDP细胞悬液建立实体瘤模型,随机分为对照组、参慈胶囊组、参慈胶囊+顺铂组、顺铂组,各10只。对照组予等量生理盐水...目的:探讨参慈胶囊对人肺腺癌A549/DDP裸鼠体内多药耐药相关基因的影响。方法:将50只C57BL/6小鼠接种人肺腺癌细胞A549/DDP细胞悬液建立实体瘤模型,随机分为对照组、参慈胶囊组、参慈胶囊+顺铂组、顺铂组,各10只。对照组予等量生理盐水,其余各组荷瘤小鼠均用药21 d,断颈处死取肿瘤组织,采用FQ-PCR技术检测人肺腺癌A549/DDP肺癌组织MDR1、MRP1、LRP m RNA的表达情况。结果:MDR1 m RNA、MRP1 m RNA、LRP1 m RNA在各组均有表达,各治疗组的MDR1m RNA、MRP1 m RNA、LRP1 m RNA均低于对照组,差异均有统计学意义(P<0.01);参慈胶囊+顺铂组的MDR1 m RNA、MRP1 m RNA、LRP1 m RNA的表达均明显低于参慈胶囊组和顺铂组,差异均有统计学意义(P<0.01)。结论:通过降低MDR1、MRP1、LRP多药耐药相关基因的表达,可能是参慈胶囊逆转人肺腺癌A549/DDP裸鼠体内多药耐药的作用机制之一。展开更多
基金Supported by the National Natural Science Foundation of China(No.81271036No.81500751)+1 种基金the Key Research Project of Shandong Province,China(No.2015GSF118121)the Natural Science Foundation of Shandong Province,China(No.ZR2015PH062)
文摘AIM：To investigate the altering expression profiles of efflux transporters such as breast cancer-resistance protein（BCRP）,lung resistance protein（LRP）,and multidrug resistance protein 1（MDR1） at the inner blood-retinal barrier（BRB） during the development of early diabetic retinopathy（DR） and/or aging in mice.METHODS：Relative m RNA and protein expression profiles of these three efflux transporters in the retina during the development of early DR and/or aging in mice were examined.The differing expression profiles of Zonula occludens 1（ ZO-1） and vascular endothelial growth factor-A（ VEGFA） in the retina as well as the perfusion characterization of fluorescein isothiocyanate（FITC）-dextran and Evans blue were examined to evaluate the integrity of the inner BRB.RESULTS：There were significant alterations in these three efflux transporters＇ expression profiles in the m RNA and protein levels of the retina during the development of diabetes mellitus and/or aging.The development of early DR was confirmed by the expression profiles of ZO-1 and VEGFA in the retina as well as the compromised integrity of the inner BRB.CONCLUSION：The expression profiles of some efflux transporters such as BCRP,LRP,and MDR1 in mice retina during diabetic and/or aging conditions are tested,and the attenuated expression of BCRP,LRP,and MDR1 along with the breakdown of the inner BRB is found,which may be linked to the pathogenesis of early DR.
文摘Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-small cell lung cancer (NSCLC) was detected using immunohistochemistry method. The expression of MRP in 30 cases of NSCLC and corresponding normal lung tissues were detected using immunohistochemistry and Western Blot. Results: this study of tumor tissues confirmed the plasma membrane and/or cytoplasm locations of MRP. There was apparent difference between normal lung tissues and NSCLC in MRP. The survival analysis of 62 NSCLC showed that the mean survival time of the patients with negative MRP expression was 69.8117.41 months and that of patients with positive MRP expression, 25.384.46 months. Log-rank test suggested that the difference between them was significant (P=0.0156). It was also found that in squamous cell lung cancer the statistically significant difference between the mean survival time of patients with positive MRP expression and those with negative MRP expression (P=0.0153). Multivariate Cox model analysis suggested that the survival time was significantly related to expression of MRP (P=0.035) and lymphatic metastasis (P=0.038). Conclusion: MRP expression in NSCLC is significantly higher compared with normal lung tissues. The mean survival time of patients with negative MRP was relative longer and expression of MRP was an independent factor for prognosis.
文摘目的研究乳腺癌组织中肺耐药蛋白(lung resistance protein,LRP)的表达,探讨其在乳腺癌多药耐药机制中的作用及其临床意义。方法2000年首都医科大学附属北京友谊医院普通外科收治的乳腺癌病例81例,均为女性,年龄30至83岁(平均年龄53.2岁),接受以手术为主的综合治疗且均未进行新辅助化疗。病理类型包括浸润性导管癌、浸润性小叶癌、单纯癌、黏液癌和早期浸润癌。根据2003版国际抗癌联盟(International Union Against Cancer,UICC)乳腺癌分期标准进行临床病理分期,Ⅰ期:17例,Ⅱ期:43例,Ⅲ期:21例。术后5年随访者36例,无瘤生存30例,转移6例(带瘤生存1例,死亡5例)。制作组织芯片,采用SP免疫组化染色法,测定81例未经过新辅助化疗的乳腺癌标本中LRP的表达,与临床病理因素及雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、抑癌基因p53(p53)、人表皮生长因子受体2(Her-2)、增生细胞核抗原Ki-67(Ki-67)的表达进行相关性分析。应用χ2检验及等级相关检验,使用SPSS11.5统计学软件进行数据处理及分析。结果乳腺癌组织中LRP的阳性表达率为70.4%(57/81)。老年患者的LRP表达比中青年患者明显降低(P<0.05);LRP的表达与病理分期、预后无相关关系(P>0.05)。LRP与ER和PR的表达存在一定的正相关关系,相关系数分别为0.327、0.264(P<0.05);LRP与p53、Her-2、和Ki-67的表达无相关关系(P>0.05)。结论LRP在乳腺癌组织中有较高的表达率,与年龄及ER、PR的表达有关,本结果为临床化疗药物的选择提供了依据。
文摘目的:探讨参慈胶囊对人肺腺癌A549/DDP裸鼠体内多药耐药相关基因的影响。方法:将50只C57BL/6小鼠接种人肺腺癌细胞A549/DDP细胞悬液建立实体瘤模型,随机分为对照组、参慈胶囊组、参慈胶囊+顺铂组、顺铂组,各10只。对照组予等量生理盐水,其余各组荷瘤小鼠均用药21 d,断颈处死取肿瘤组织,采用FQ-PCR技术检测人肺腺癌A549/DDP肺癌组织MDR1、MRP1、LRP m RNA的表达情况。结果:MDR1 m RNA、MRP1 m RNA、LRP1 m RNA在各组均有表达,各治疗组的MDR1m RNA、MRP1 m RNA、LRP1 m RNA均低于对照组,差异均有统计学意义(P<0.01);参慈胶囊+顺铂组的MDR1 m RNA、MRP1 m RNA、LRP1 m RNA的表达均明显低于参慈胶囊组和顺铂组,差异均有统计学意义(P<0.01)。结论:通过降低MDR1、MRP1、LRP多药耐药相关基因的表达,可能是参慈胶囊逆转人肺腺癌A549/DDP裸鼠体内多药耐药的作用机制之一。
